Natalizumab may be appropriate for some patients as an alternative to cytotoxic therapy for multiple sclerosis (MS), a vignette study has found.
The clinical review of natalizumab used the format of a case vignette followed by discussion of natalizumab as a potential therapy.
The case was of a woman aged 30 diagnosed with MS two years previously. Interferon-beta was not tolerated due to worsening of depression. Despite treatment with glatiramer and high-dose corticosteroid, she had three recent acute attacks and is being considered for natalizumab.
The author briefly discusses the effects and epidemiology of MS, noting its a high impact on quality of life, and cost